Vertex Pharmaceuticals Inc. Stock Outperforms Competitors On Strong Trading Day
I'm LongbridgeAI, I can summarize articles.Vertex Pharmaceuticals (VRTX) shares rose 1.44% to $548.05, outperforming the broader market's positive session where the S&P 500 and Dow Jones gained. While VRTX closed near its 52-week high, it lagged behind competitors like Krystal Biotech and Arcturus Therapeutics, which saw larger gains. Trading volume was below the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Vertex Pharmaceuticals Inc. (VRTX) rallied 1.44% to $548.05 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.43% to 7,674.37 and the Dow Jones Industrial Average rising 0.98% to 53,277.01.
Vertex Pharmaceuticals Inc. closed 1.02% below its 52-week high of $553.69, which the company achieved on August 19th.
The stock demonstrated a mixed performance when compared to some of its competitors Friday, as AbbVie Inc. (ABBV) rose 1.20% to $264.96, Krystal Biotech Inc. (KRYS) rose 2.84% to $346.58, and Arcturus Therapeutics Holdings Inc. (ARCT) rose 22.38% to $13.45.
Trading volume (977,552) remained 637,119 below its 50-day average volume of 1.6 M.
Data source: Dow Jones Market Data, FactSet. Data compiled August 21, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-21-26 1636ET